Cargando…

Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population

Severe Strongyloides stercoralis, such as hyperinfection syndrome, carries a high mortality risk. Even with appropriate treatment, patients may experience infectious complications and failure of therapy. Currently, there are no Food and Drug Administration–approved parenteral therapies available for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeitler, Kristen, Jariwala, Ripal, Restrepo-Jaramillo, Ricardo, Kapadia, Shyam, Casanas, Beata, Alrabaa, Sally, Sriaroon, Chakrapol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990086/
https://www.ncbi.nlm.nih.gov/pubmed/29866667
http://dx.doi.org/10.1136/bcr-2017-223138
_version_ 1783329554982502400
author Zeitler, Kristen
Jariwala, Ripal
Restrepo-Jaramillo, Ricardo
Kapadia, Shyam
Casanas, Beata
Alrabaa, Sally
Sriaroon, Chakrapol
author_facet Zeitler, Kristen
Jariwala, Ripal
Restrepo-Jaramillo, Ricardo
Kapadia, Shyam
Casanas, Beata
Alrabaa, Sally
Sriaroon, Chakrapol
author_sort Zeitler, Kristen
collection PubMed
description Severe Strongyloides stercoralis, such as hyperinfection syndrome, carries a high mortality risk. Even with appropriate treatment, patients may experience infectious complications and failure of therapy. Currently, there are no Food and Drug Administration–approved parenteral therapies available for treatment in patients who develop gastrointestinal complications from hyperinfection, including small bowel obstruction. A veterinary form of ivermectin is available as a subcutaneous injection, although current literature in humans is limited. We report on the successful treatment of two surviving immunocompromised patients with S. stercoralis hyperinfection syndrome after prompt recognition and initiation of veterinary subcutaneous ivermectin therapy.
format Online
Article
Text
id pubmed-5990086
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-59900862018-06-08 Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population Zeitler, Kristen Jariwala, Ripal Restrepo-Jaramillo, Ricardo Kapadia, Shyam Casanas, Beata Alrabaa, Sally Sriaroon, Chakrapol BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Severe Strongyloides stercoralis, such as hyperinfection syndrome, carries a high mortality risk. Even with appropriate treatment, patients may experience infectious complications and failure of therapy. Currently, there are no Food and Drug Administration–approved parenteral therapies available for treatment in patients who develop gastrointestinal complications from hyperinfection, including small bowel obstruction. A veterinary form of ivermectin is available as a subcutaneous injection, although current literature in humans is limited. We report on the successful treatment of two surviving immunocompromised patients with S. stercoralis hyperinfection syndrome after prompt recognition and initiation of veterinary subcutaneous ivermectin therapy. BMJ Publishing Group 2018-06-04 /pmc/articles/PMC5990086/ /pubmed/29866667 http://dx.doi.org/10.1136/bcr-2017-223138 Text en © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Zeitler, Kristen
Jariwala, Ripal
Restrepo-Jaramillo, Ricardo
Kapadia, Shyam
Casanas, Beata
Alrabaa, Sally
Sriaroon, Chakrapol
Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
title Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
title_full Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
title_fullStr Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
title_full_unstemmed Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
title_short Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
title_sort successful use of subcutaneous ivermectin for the treatment of strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
topic Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990086/
https://www.ncbi.nlm.nih.gov/pubmed/29866667
http://dx.doi.org/10.1136/bcr-2017-223138
work_keys_str_mv AT zeitlerkristen successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation
AT jariwalaripal successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation
AT restrepojaramilloricardo successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation
AT kapadiashyam successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation
AT casanasbeata successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation
AT alrabaasally successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation
AT sriaroonchakrapol successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation